Prognostic impact of the conditioning intensity on outcomes after allogeneic transplantation for MDS with low blasts: a nationwide retrospective study by the adult MDS working group of the Japan Society for Transplantation and Cellular Therapy.
Hidehiro ItonagaYasushi MiyazakiMachiko FujiokaJun AokiKazuteru OhashiTetsuya NishidaTakahiro FukudaNaoyuki UchidaYasunori UedaYasufumi UeharaYuta KatayamaShuichi OtaToshiro KawakitaJun KatoKen-Ichi MatsuokaTetsuya EtoMakoto OnizukaTatsuo IchinoheYoshiko AtsutaKen IshiyamaPublished in: Bone marrow transplantation (2024)
Poor prognostic factors, such as transfusion dependency and chromosomal risk, need to be considered in the indication of allogeneic hematopoietic cell transplantation (allo-HCT) for patients harboring myelodysplastic syndromes with less than 5% marrow blasts (MDS-Lo). We analyzed the post-transplant outcomes of 1229 MDS-Lo patients who received myeloablative (MAC)(n = 651), reduced-intensity (RIC)(n = 397), and non-myeloablative conditioning (NMAC) regimens (n = 181). The multivariate analysis revealed that the RIC group had better chronic graft-versus-host disease (GVHD)- and relapse-free survival (CRFS) (P = 0.021), and GVHD- and relapse-free survival (GRFS) than the MAC group (P = 0.001), while no significant differences were observed between the NMAC and MAC groups. In the subgroup analysis, the MAC group has better overall survival (P = 0.008) than the RIC group among patients with an HCT-comorbidity index (HCT-CI) score of 0, while the RIC group had better overall survival (P = 0.029) than the MAC group among those with an HCT-CI score ≥3. According to the type of conditioning regimen, total body irradiation 12 Gy-based MAC regimen showed better OS and CRFS than the other MAC regimen, and comparable outcomes to the RIC regimen. In conclusion, the RIC and NMAC regimens are promising options for MDS-Lo patients in addition to the MAC regimen.
Keyphrases
- free survival
- prognostic factors
- stem cell transplantation
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- allogeneic hematopoietic stem cell transplantation
- bone marrow
- peritoneal dialysis
- high intensity
- clinical trial
- cell cycle arrest
- patient reported outcomes
- skeletal muscle
- radiation therapy
- cell proliferation
- young adults
- metabolic syndrome
- cell death
- single cell
- copy number
- data analysis
- study protocol
- open label
- placebo controlled
- phase iii